Introduced by Cytel in 2015, Enforesys is a feasibility study decision-making tool for predicting recruitment milestones. Enforsys utilizes historical study site-level data and simulation models to calculate a numerical probability of success for study enrollment strategies. Compass Compass is used by biostatisticians and clinicians to plan and design earlier stage adaptive clinical trials (traditionally known as phase 1 human tolerance and phase 2 dose-selection studies). Compass is the first commercially offered adaptive trial composition software with both frequentist and Bayesian methods. Other key capabilities include R code integration, trial simulation compute engines, plus various tables, charts and graphs to visualize and communicate trial design attributes. StatXact Statistical software based on the exact branch of statistics used for small-sample categorical and nonparametric data problem-solving. Utilized by statisticians and researchers in all fields of study, the StatXact software now has 150 different non-parametric statistical tests and procedures. Initially offered in 1989 as StatXact DOS, StatXact 8 was released in 2007. The StatXact PROCs variant integrates with the popular SAS statistical software. LogXact A logistic regression predictive modeling software package suited particularly to cases involving small samples and / or missing data. Logistic regression is used extensively in the medical and social sciences as well as marketing applications to predict subject behavior. First made available in 1996 under the name LogXact Turbo, LogXact was introduced in 2007 and is currently in its eleventh release. The LogXact PROCs variant integrates with the popular SAS statistical software. ACES Cytel's web-based Access Controlled Execution System. ACES simplifies compliance with the related FDA guidance and EMA guidelines by a secure means of communicating a clinical trial's interim analysis results and recommendations between the Data Monitoring Committee (DMC/DSMB), Independent Statistical Center and clinical team members. The validated system automatically creates an audit trial, allowing regulators to readily determine "who saw what and when". SiZ In 2012, SiZ as a stand-alone product was deprecated, and its feature set was consolidated into the company's East product. OK GO OK GO is the first commercially available software to support the implementation of a quantitative go/no-go decision-making framework in clinical trials. Locations United States Cambridge, Massachusetts (HQ) Waltham, MA King of Prussia, PA San Jose, CA Canada Toronto, ON Vancouver, BC Europe Geneva, CH Paris, FR Barcelona, ES Basel, CH London, UK Rotterdam, NL Asia Shanghai, CN Singapore, SG India Pune Hyderabad Bengaluru Mumbai Ahmedabad See also Biostatistics Clinical research Drug development